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Cytology and histology records and cervical samples for HPV assay were obtained from a prospective cohort of 49655 women
attending clinics for routine cervical cytology in or near Manchester between 1988 and 1993. The women were followed up for
cytological abnormality and neoplasia through the cytology laboratory’s records. HPV at entry was assayed in an age- and period-
stratified random sample of 7278 women and in prevalent and incident CIN3 cases. The prevalence of newly diagnosed CIN3
increased with time since last normal smear, indicating that most cases persist for several years. CIN3 prevalence did not increase
further for screening intervals exceeding 5 years, however, suggesting that CIN3 eventually regresses cytologically. CIN2 prevalence
increased less steeply with screening interval, while the prevalence of lesser abnormality was almost independent of screening interval.
The prevalence of oncogenic HPV at entry declined from 19% among women aged under 25 to less than 3% at age 40 or above.
Oncogenic HPV infection was strongly predictive of subsequent CIN3 (OR 17.2, 95% CI 10.4–28.4), but only weakly related to CIN2
(OR 2.3, 95% CI 0.5–10.7) and lesser abnormality (OR 1.4, 95% CI 0.8–2.5). At current incidence rates, the lifetime risk of
developing CIN3 will be 9% in this population. The cumulative risk of CIN3 diagnosis among cytologically normal women with
oncogenic HPV detected at entry was 28% (CI 18–43%) after 14 years. Persistence of oncogenic HPV may be more sensitive and
specific than cytology for early detection of CIN3 and invasive cancer.
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Population-based prospective data on cervical neoplasia rates in
relation to age, screening interval and history of type-specific HPV
infection are still limited. Few cohorts are representative of
regularly screened women in the general population, and those
using the Bethesda system under which the high-grade category
(HSIL) includes both CIN2 and CIN3 (Solomon et al, 2002) have
often not analysed CIN2 and CIN3 separately. There is a strong and
consistent association of genital HPV infection with cervical
intraepithelial neoplasia (CIN) and cancer. CIN3 is almost always
preceded by persistently detectable oncogenic HPV (Nobbenhuis
et al, 1999), and HPV DNA was present in virtually all (99.7%) of a
large sample of cervical cancers obtained from populations
worldwide (Walboomers et al, 1999). Uninfected women, including
those with abnormal cytology, are thus at negligible risk of
invasive cancer. Follow-up studies indicate that most HPV
infections are transient (Hildesheim et al, 1994; Remmink et al,
1995; Ho et al, 1998; Liaw et al, 1999; Nobbenhuis et al, 1999), but
women with persistent HPV are at high risk of developing CIN3
(Nobbenhuis et al, 1999, 2001). HPV testing could thus be superior
to cytology in routine cervical screening (Nobbenhuis et al, 1999;
Cuzick et al, 2003).
This report describes the relationship between HPV detection
at entry and cytological and histological follow-up based
on routine laboratory records in a prospective population-based
cohort of 61564 women recruited between 1987 and 1993.
Each woman contributed at least one cervical sample for HPV
analysis at a routine cervical smear test. Since the national cervical
screening programme was launched in 1988, all British women
aged 20–64 have been invited for cervical screening every
3–5 years, according to regional policy. Many women were
therefore being screened for the first time. The cohort, in which
86% of screening intervals were over 2 years, is contemporary with
the Portland cohort of over 20000 American women in a health
care plan with a policy of annual screening (Liaw et al, 1999;
Sherman et al, 2003). The resulting differences in outcome
are informative in relation to natural history as well as screening
policy.
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Recruitment of the cohort
Between 1987 and 1993, in collaboration with over 100 general
practitioners and screening clinics in the Greater Manchester area
who used the Christie Hospital cytology laboratory (now the
Manchester Cytology Centre sited at Manchester Royal Infirmary),
78062 cervical cell samples were collected from 61564 women
attending for routine screening. There was no age restriction.
Participating practices and clinics covered a wide area in and
around the city of Manchester, and offered screening either in the
context of well-woman clinics or in association with family-
planning services.
The study was approved by the local ethics committee. Verbal
informed consent obtained when the smear was taken was deemed
appropriate, as the study database was anonymised, and the clinical
significance of HPV infection was not then known. HPV assays
were performed after recruitment had ended, and no HPV results
were reported either to the cytology laboratory or to the women.
At recruitment, a cervical smear was obtained from each
woman, usually using an Ayre spatula. A second scrape was then
taken using the same spatula and the tip, together with adherent
cervical cells, was broken off into a sterile container containing
10ml of storage buffer (0.9% PBS (pH 7.2) þ0.1% SDS). Spatula
samples were sent together with the corresponding smears and
pathology request forms to the Christie Hospital Cytology
Department. Smears that were accompanied by a spatula were
flagged on receipt on the laboratory database. The name, address
and date of birth are routinely used by the cytology laboratory to
match new smears against a woman’s previous screening record.
Spatulas were vortexed, and the cell suspensions transferred to
freezer tubes, which were stored at  301C. Samples taken before
July 1988 were centrifuged and only the pellet was stored. These
pelleted samples were deemed unsatisfactory for HPV assay, so all
analyses are restricted to the 54060 women who provided a sample
on or after 1st July 1988.
Structure of the study database
As a sampling frame for studies nested within the cohort, the
78062 spatulas were stratified according to the 12-month period in
which they were taken and 5-year age groups. To avoid the cost of
testing all spatulas for HPV DNA, we used this sampling frame to
select an age- and period-stratified random sample for HPV assay.
Entry spatulas for CIN3 diagnoses notified up to June 1998 were
also assayed.
Smear and histology results in the study database were updated
at 6-monthly intervals during recruitment from laboratory records.
Matching was on laboratory number, so named data were not
required. The database was updated in the same way after
recruitment had ended, and the present report includes cytology
results for all smears recorded up to the end of January 1996 and
histology results for biopsies taken up to the end of December
1998. (Follow-up is incomplete for symptomatic cancers, which
would not necessarily be linked to the laboratory records.) In
addition, screening histories of 232 women in the HPV-tested
random sample who were cytologically normal but were infected
with an oncogenic HPV type at entry were updated by matching
against the laboratory’s current database to extend their follow-up
to the end of June 2002 for cytology and to the end of March 2004
for histology.
Detection of HPV DNA
PCR analysis followed recommended anticontamination proce-
dures (Bauer et al, 1992). Spatula samples were thawed at room
temperature and resuspended. The cell pellets obtained from
centrifugation of 250ml suspension were washed in normal saline
to remove the collection buffer, then resuspended and digested
with 200mgml
 1 proteinase K by incubation at 551C for 1h in 25ml
50mM Tris-HCl buffer (pH 8.5) containing 1mM EDTA (TE
buffer), 1% (vv
 1) Tween-20. The protease was inactivated by
incubation at 951C for 10min and the crude digests were made up
to 250ml in TE buffer. Aliquots, 5ml, of the digests were then used
for HPV L1 consensus PCR amplification in 100ml reaction volume
using the MY09/MY11 primers (Manos et al, 1989; Bauer et al,
1992). A 286bp human b-globin fragment was amplified
simultaneously in all samples to act as an internal PCR control.
PCR-negative controls, and HPV-positive (SiHa cells) and negative
controls were run in each experiment. Overall, 89% of all samples
assayed gave a satisfactory (i.e. b-globin positive) HPV result.
Aliquots, 10ml, of PCR product were run on agarose gel, vacuum
blotted onto nylon membranes and immobilised by UV cross-
linking. Membranes were hybridised with a b-globin oligonucleo-
tide probe, then with a generic HPV probe in order to determine
HPV positivity. Biotin-labelled probes were used and positive
hybridisation was detected using enhanced chemoluminescence.
Positive samples were dot blotted onto new membranes and
hybridised with a series of biotinylated type-specific probes
including 6/11/42 (mixed), 16, 18, 26, 31, 33, 35, 39, 40, 45, 51,
52, 53, 54, 55, 56, 57, 58, 59, 66, 68, 73, 82, 83 and 84. Samples
positive with the generic probe but negative on all dot blots were
considered positive but untyped.
STATISTICAL METHODS
Definition of diagnosis dates
There is no entirely satisfactory definition of the date of diagnosis
of CIN3. The final phase of persistent cytological abnormality is
frequently interrupted by a normal smear but may also be
preceded by an isolated abnormal smear several years earlier. The
date of histological diagnosis is not appropriate, as more than a
year may elapse between the first of a series of abnormal smears
and eventual histological confirmation, and this interval is
determined as much by referral practice as by the rate of
progression. As a practicable compromise, we have defined the
date of CIN3 diagnosis in all analyses as the date of the first
abnormal smear in the 2 years preceding histological confirmation
of CIN3. Dates of CIN2 or cancer diagnosis were defined in the
same way. Two cases of CIN3 which were diagnosed histologically
between entry to the study and the following smear date, both in
the third year of follow-up, in women with no recorded abnormal
smear were ignored. Smears classified as cytologically inadequate
were ignored in all analyses, but those that were infected but
adequate were classified as normal. Abnormal smear results not
followed within 2 years by histological diagnosis of CIN2 or CIN3
were classified as ‘lesser abnormality’. All adequate smears were
thus classified as cytologically normal, lesser abnormality, CIN2,
CIN3 or cancer. CIN3 and cancer were combined in most analyses.
Definition of the cohorts
The present report is based on 54060 women who entered the
study on or after 1 July 1988 (Figure 1). The first cytologically
adequate routine smear (defined as a smear not preceded by an
abnormal smear within the previous year) at which a spatula
sample for HPV assay was also taken defined a woman’s entry
date. Women were ineligible if their entry smear was inadequate
(n¼3391), they had a record of an abnormal smear within the
previous year (n¼509), or they had ever had a diagnosis of CIN3
(n¼505). All analyses are based on the remaining 49655 women
from whom a sample for HPV assay was collected at a routine
smear test that gave an adequate cytological result.
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retrospective cohort, which comprised 35610 women whose
previous smear was cytologically normal and routine (i.e. not
preceded within a year by an abnormal smear), was completely
followed up from the previous smear date to the entry smear date.
Women with an abnormal entry smear at which CIN2 or CIN3 was
diagnosed were the incident cases in the retrospective cohort. The
prospective cohort, comprising 28658 women whose entry smear
was normal and who had a subsequent cytologically adequate
smear, were followed from the entry smear to the following smear.
Women with no record of a previous smear were included. HPV
testing of entry smears was restricted to women who had at least
one previous cytologically adequate smear recorded on the
database. Entry spatulas for 7278 of these women were included
in the age-stratified random sample of all spatulas. These 7278
spatulas were assayed for HPV, and a satisfactory (b-globin
positive) result was obtained for 6462 (89%). These 6462 women
are referred to as the random cohort.
The entry smear in the retrospective cohort and the next smear
in the prospective cohort were categorised by 5-year age strata and
time since the preceding normal smear for analysis by uncondi-
tional logistic regression of the odds ratios for CIN3, CIN2 and
lesser abnormality. The underlying incidence of CIN3, estimated
by dividing the number of cases by the woman-years of follow-up
since the last smear within each age and interval stratum, was
analysed by Poisson regression. HPV analysis was performed
systematically on all entry spatulas (i) for the 7278 eligible women
in the age-stratified random sample (ii) for all CIN3 cases
diagnosed at entry and (iii) for subsequent CIN3 cases notified
within the study period (i.e. with histology before the end of 1993).
HPV status at entry was determined for 87% (314 out of 361) of
prevalent CIN3 cases diagnosed at entry and for 41% (84 of 204) of
incident cases diagnosed at the next routine smear. Logistic
regression analysis was used within this nested case–control study
to determine the effect of HPV infection in a normal smear on the
risk of cytological abnormality at the following smear. Confidence
61 564 women 
(78 062 spatulas) 
54 060 women with  
nonpelleted samples 
Excluded: 
7504 with no spatula taken after July 1988 
A random sample of 7278 
samples HPV tested 
Random cohort:  
6462 with satisfactory HPV 
result at entry (-globin+) 
49 655 women potentially 
eligible for both cohorts 
Excluded: 
• 3391 with inadequate entry smear  
• 505 with previous CIN 3  
• 509 with abnormal smear in preceding year  
35 610 women enter 
retrospective cohort 
28 658 women enter 
prospective cohort 
Excluded from retrospective cohort: 
• 612 whose previous smear was 
preceded within a year by an abnormal 
smear  
• 13 084 without a previous smear 
• 349 whose previous smear was 
abnormal 
Excluded from prospective cohort: 
• 18 379 with no further smears 
• 2618 with abnormal entry smear 
Entry smear (HPV test) Previous smear  Next smear 
Diagnosis of CIN 3 cases in 
retrospective cohort 
Diagnosis of CIN 3 cases 
in prospective cohort 
Figure 1 Definition of the cohorts.
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levels are two-sided. The cumulative risk for diagnosis of CIN3 or
cancer was calculated by the Kaplan–Meier method, defining
diagnosis date as described above and censoring at the latest
recorded smear date.
RESULTS
Age-specific prevalence of HPV, cytological abnormality,
CIN3 and cancer at entry
Table 1 shows the prevalence of CIN3 or cancer, CIN2 and lesser
abnormality at entry among the 49655 eligible women. There were
28 cancers, 333 CIN3s and 200 CIN2s. Rates are similar at each age
in women with and without a previous smear. Most of the 13084
previously unscreened women were aged either under 25 (56%) or
55 or over (10%). Table 2 shows the age-specific prevalence of
HPV infection at entry in the random cohort of 6462 HPV-typed
women. The prevalence of HPV declined from 23% among women
aged under 25 to less than 4% above age 40. There is a less marked
trend in women whose index smear was cytologically abnormal,
among whom the prevalence declines from 68% (41 out of 60)
below age 25 to 36% (33 out of 92) above age 40. In all, 75% (460
out of 617) of HPV infections included a high-risk type (listed in
Table 2 footnote), and 35% (216 out of 617) included HPV16. The
prevalence of HPV16 was 9% (76 out of 845) below age 25, 4% (82
out of 1910) at age 25–34 and 2% (58 out of 3707) at age 35 or
over. In subsequent tables, only high-risk HPV (HR-HPV) types
are considered, and cancers are included with CIN3 (designated
CIN3þ).
Prevalences of CIN3þ, CIN2 and lesser abnormality at entry to
the study and concurrent HR-HPV infection rates are summarised
in Table 3. The prevalence of abnormality of any grade was 7%
Table 1 Prevalence of cytological abnormality and neoplasia at entry to the study
Result at entry smear
CIN3 or cancer
a CIN2 Lesser abnormality All women
No previous
smears
Previous
smears
No previous
smears
Previous
smears
No previous
smears
Previous
smears No previous
smears
Previous
smears
Age at entry smear No. % No. % No. % No. % No. % No. %
15–19 5 (0) 0.2 3 (0) 0.3 4 0.1 5 0.5 160 5.2 65 5.9 3106 1099
20–24 17 (1) 0.4 28 (0) 0.5 16 0.4 33 0.6 270 6.5 353 6.3 4164 5572
25–29 16 (1) 0.8 79 (3) 1.3 17 0.9 29 0.5 112 5.8 345 5.6 1924 6179
30–34 9 (1) 1.1 74 (8) 1.5 2 0.3 28 0.6 33 4.1 201 4.1 803 4953
35–39 9 (1) 1.7 43 (3) 1.0 5 1.0 27 0.6 18 3.5 161 3.7 519 4365
40–44 3 (0) 0.7 29 (3) 0.7 2 0.5 17 0.4 22 5.0 148 3.6 443 4083
45–49 1 (0) 0.3 14 (1) 0.5 0 0.0 3 0.1 6 1.8 73 2.6 340 2857
50–54 1 (0) 0.2 13 (1) 0.5 0 0.0 9 0.4 10 2.3 41 1.6 435 2595
55+ 9 (4) 0.7 8 (1) 0.2 0 0.0 3 0.1 11 0.8 28 0.6 1350 4868
All ages 70 (8) 0.5 291(20) 0.8 46 0.1 154 0.4 642 4.9 1415 3.9 13084 36571
All women 361 200 2057 49655
aNumbers and prevalence rates include cancer and CIN3. Cancers are also shown separately in brackets.
Table 2 Randomly selected cohort: HPV prevalence by cytology result of index smear
Normal smear
a Any abnormality Total
Any HPV High risk
b HPV Any HPV High risk
b HPV Any HPV High-risk
b HPV HPV 16
Age Total n % n % Total n % n % Total n % n % n %
15–19 319 64 20.1 55 17.2 19 17 89.5 14 73.7 338 81 24.0 69 20.4 33 9.8
20–24 466 89 19.1 75 16.1 41 24 58.5 17 41.5 507 113 22.3 92 18.2 43 8.5
25–29 586 81 13.8 61 10.4 61 38 62.3 32 52.5 647 119 18.4 93 14.4 40 6.2
30–34 1191 96 8.1 53 4.5 72 35 48.6 33 45.8 1263 131 10.4 86 6.8 42 3.3
35–39 914 36 3.9 23 2.5 49 26 53.1 24 49.0 963 62 6.4 47 4.9 22 2.3
40–44 926 26 2.8 15 1.6 46 17 37.0 13 28.3 972 43 4.4 28 2.9 13 1.4
45–49 508 18 3.5 11 2.2 19 4 21.1 4 21.1 527 22 4.2 15 2.9 6 1.1
50–54 1104 32 2.9 18 1.6 27 12 44.4 11 40.7 1131 44 3.9 29 2.6 17 1.5
55–69 114 2 1.8 1 0.9 — — — — — 114 2 1.8 1 0.9 — —
Total 6128 444 7.3 312 5.1 334 173 51.8 148 44.3 6462 617 9.6 460 7.1 216 3.3
aIncludes 175 with infection.
bHigh-risk HPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68. Prevalence of each HR-HPV type among the 460 HR-HPV infected
women in the random cohort overall, and without another HR-HPV type: HPV16: 47.0%, 39.8%. HPV18: 16.7%, 12.0%. HPV26: 0.0%, 0.0%. HPV31: 13.0%, 8.7%. HPV33: 8.5%,
6.5%. HPV35: 1.1%, 0.7%. HPV39: 2.4%, 0.9%. HPV45: 4.8%, 3.5%. HPV51: 0.7%, 0.2%. HPV52: 3.9%, 2.0%. HPV53: 7.4%, 3.3%. HPV56: 5.0%, 2.0%. HPV58: 6.3%, 3.7%. HPV59:
1.7%, 1.3%. HPV66: 0.0%, 0.0%. HPV68: 0.0%, 0.0%.
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44 and 2% (230 out of 12445) at age 45 or over. High-grade disease
(CIN2 or CIN3þ) was present in 21% (561 out of 2618) of
abnormal entry smears. HR-HPV was detected in the abnormal
entry smear in 82% (257 out of 314) of prevalent CIN3þ cases,
with a slightly higher rate in younger women. A second spatula was
taken before the diagnostic biopsy in 21 of the 57 prevalent
CIN3þ cases whose entry spatula was HR-HPV negative, and 13
(62%) were HR-HPV positive. The prevalence of HR-HPV at entry
among cytologically normal women in whom CIN3þ was
diagnosed at the next routine smear was 50% overall (42 out of
84: Table 3, right-hand column). This prevalence was similar in
smears taken less than 3 years before CIN3 diagnosis (51%:20 out
of 39) or 3 or more years earlier (49%:22 out of 45).
Prevalence rates at the next smear for CIN3þ, CIN2 and lesser
abnormality in the combined prospective and retrospective
cohorts are shown in Table 4 by age, interval since the preceding
normal smear and history of earlier cytological abnormality.
Women whose next smear was taken below age 20 (n¼1611) or
after an interval of 10 or more years (n¼1821) are excluded in
Table 4. ORs were estimated by multivariate unconditional logistic
regression analysis of the categorical variables shown in Table 4.
Separate analyses of the retrospective and prospective data (not
shown) gave similar results. The cohort indicator variable included
in the combined analysis suggests a slightly lower prevalence of all
three grades of abnormality in the retrospective cohort, although
the difference was statistically significant only for lesser abnorm-
ality (retrospective: prospective OR 0.88, CI 0.81–0.96). The
prevalence of CIN3þ increased from age 20–24 to a maximum at
age 30–34 and then declined at older ages. In contrast, both CIN2
and lesser abnormality were most prevalent at age 20–24 and
declined steadily with increasing age.
All three grades of neoplasia showed a statistically significant
trend in OR with increasing screening interval, but the rate of
increase was greater for CIN3þ than for CIN2, and the prevalence
of lesser abnormality was almost constant (Figure 2). Smears taken
after an interval of 3–4 years were taken as the reference group
(OR¼1.0) in the corresponding analysis in Table 4. The
prevalence of CIN3þ was 0.2% within a year of a normal smear
(OR 0.16, CI 0.05–0.49) and increased by a factor of 1.49 per year
(CI 1.33–1.67, Po0.001) for intervals of under 5 years, reaching a
maximum of 1.0% (OR 1.53, CI 1.15–2.03) between 4 and 5 years.
CIN3þ prevalence was 0.8% (OR 1.43, CI 1.09–1.89) for intervals
between 5 and 10 years, showing no further increase. CIN2 was
more common than CIN3þ initially and increased by a factor of
1.22 (CI 1.05–1.41, Po0.01) per year up to 5 years. The ratio of
CIN2 to CIN3þ showed a significant (Po0.005) initial decline,
from 1.5 (19:13) in smears taken within 18 months of a normal
smear to 0.5 (211:415) thereafter. The OR for lesser cytological
abnormality increased by only 1.05 (CI 1.00–1.10, P¼0.03) per
year since the last normal smear, from 1.03 (CI 0.82–1.29) below a
year to 1.30 (CI 1.13–1.49) at 4–5 years and 1.18 (CI 1.03–1.35)
beyond 5 years. The multivariate analysis shown in Table 4 was
repeated for CIN2, taking women with lesser abnormality as the
control group. The age distributions were similar, and the only
difference between CIN2 and lesser abnormality was the slightly
steeper trend in CIN2 with increasing screening interval (P¼0.07).
The linear increase in CIN3þ prevalence with increasing
screening interval up to 5 years (Figure 2; P trendo0.001) suggests
that most new cases persist for at least 5 years. We therefore fitted
the same multivariate model by Poisson regression, including the
variables shown in Table 4 but replacing each smear by the
number of woman-years since the last smear in the denominator.
This corresponds to an analysis of the underlying incidence of
CIN3þ (annual rate of development of new cases) on the
assumption that new cases remain detectable at least until the
next smear. The estimates for age and other variables were
virtually unaltered, but relative risk (RR) estimates for different
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year up to 5 years. Relative risks and CIs for intervals of o1, 1–,
2–, 3– and 4–4.9 years were 0.67 (0.21–2.11), 0.95 (0.63–1.44),
1.07 (0.82–1.39), 1.0 (reference) and 1.13 (0.85–1.50), respectively.
For smears taken after 5 years or longer, however, the RR for
CIN3þ incidence was less than for shorter intervals (RR 0.74, CI
0.58–0.95, Po0.02). The underlying age-specific incidence of CIN3
in a screened population can thus be estimated from data on
screening intervals not exceeding 5 years. In Table 5, which is
based on all screening intervals under 5 years in the retrospective
and prospective cohorts, woman-years from the routine normal
smear to the following smear and incident cases of CIN3þ are
tabulated according to the woman’s age at the midpoint of
the screening interval. Figure 3 shows the corresponding annual
incidence of CIN3þ together with the age-specific prevalence
of HR-HPV. The incidence of CIN3þ reaches a maximum of
0.004 per year at age 25–29 and declines steadily to less than 0.001
per year above age 45. These incidence rates imply a cumulative
risk of developing CIN3þ of 7.8% by age 45 and 9.0% by age 65
(Table 5).
Table 4 Prevalence of CIN3+, CIN2 and lesser abnormality by interval since last normal smear and age
CIN3+ CIN2 Lesser abnormality
Prevalence (n) OR (95% CI) Prevalence (n) OR (95% CI) Prevalence (n) OR (95% CI) Total smears (n)
Total 0.70% (428) 0.38% (230) 3.82% (2324) 60836
Age at smear:
20–24 0.69% (65) 0.84 (0.61, 1.15) 0.59% (56) 1.15 (0.79, 1.68) 6.13% (581) 1.19 (1.05, 1.35) 9471
25–29 0.96% (107) 1.00 0.57% (63) 1.00 5.29% (587) 1.00 11093
30–34 1.23% (107) 1.18 (0.90, 1.55) 0.48% (42) 0.81 (0.54, 1.20) 4.10% (358) 0.76 (0.66, 0.87) 8729
35–39 0.78% (57) 0.71 (0.51, 0.98) 0.42% (31) 0.68 (0.44, 1.05) 3.80% (279) 0.69 (0.60, 0.80) 7334
40–44 0.67% (45) 0.58 (0.40, 0.82) 0.31% (21) 0.48 (0.29, 0.80) 3.31% (222) 0.59 (0.51, 0.70) 6708
45–49 0.37% (19) 0.30 (0.19, 0.50) 0.08% (4) 0.17 (0.04, 0.32) 3.18% (164) 0.56 (0.47, 0.67) 5156
50–54 0.28% (12) 0.23 (0.13, 0.42) 0.24% (10) 0.35 (0.18, 0.68) 1.65% (70) 0.29 (0.22, 0.37) 4234
55+ 0.20% (16) 0.15 (0.09, 0.26) 0.04% (3) 0.05 (0.02, 0.16) 0.78% (63) 0.13 (0.10, 0.17) 8111
Screening interval:
o1 year 0.16% (3) 0.16 (0.05, 0.49) 0.47% (9) 0.80 (0.40, 1.62) 4.89% (93) 1.03 (0.82, 1.29) 1903
1–1.9 years 0.40% (27) 0.41 (0.27, 0.63) 0.31% (21) 0.56 (0.34, 0.92) 4.15% (279) 0.90 (0.78, 1.04) 6717
2–2.9 years 0.67% (90) 0.85 (0.65, 1.10) 0.35% (48) 0.82 (0.57, 1.18) 4.39% (594) 1.15 (1.03, 1.29) 13533
3–3.9 years 0.71% (150) 1.00 0.38% (80) 1.00 3.45% (731) 1.00 21181
4–4.9 years 1.01% (72) 1.53 (1.15, 2.03) 0.41% (29) 1.19 (0.77, 1.82) 4.15% (295) 1.30 (1.13, 1.49) 7100
5–9.9 years 0.83% (86) 1.43 (1.09, 1.89) 0.41% (43) 1.49 (1.01, 2.19) 3.19% (332) 1.18 (1.03, 1.35) 10402
Previous abnormality:
No 0.65% (292) 1.00 0.33% (145) 1.00 3.39% (1511) 1.00 44611
Yes 1.42% (36) 3.02 (2.11, 4.32) 0.75% (19) 2.84 (1.73, 4.66) 6.19% (157) 2.00 (1.68, 2.38) 2536
No previous smear 0.73% (100) 0.95 (0.74, 1.21) 0.48% (66) 1.04 (0.75, 1.43) 4.79% (656) 1.06 (0.95, 1.17) 13689
Cohort:
Prospective 0.70% (197) 1.00 0.40% (112) 1.00 4.02% (1130) 1.00 28102
Retrospective 0.71% (231) 0.92 (0.76, 1.12) 0.36% (118) 0.83 (0.64, 1.08) 3.65% (1194) 0.88 (0.81, 0.96) 32734
Odds ratios were estimated by multivariate logistic regression analysis, fitting all variables shown.
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The random cohort included 232 cytologically normal women with
HR-HPV at entry and at least one later smear who were followed
cytologically for up to 14 years. In all, 15% developed histologically
confirmed CIN3þ (28 CIN3s and six cancers), giving a cumulative
actuarial CIN3þ diagnosis rate of 16% (CI 11–23%) after 10 years
and 28% (CI 18–43%) after 14 years (Figure 4).
The high risk of subsequent CIN3þ in women with HR-HPV
infection is apparent from Table 6. Among women with HR-HPV
but normal cytology at entry, the proportion whose following
smear was abnormal was 16% (36 out of 232). The majority (20)
of these 36 abnormal smears had underlying CIN3þ, two
had CIN2 and the remaining 14 had lesser abnormality. The
prevalence of CIN3 increased with age, but the trend was not
significant. In contrast, the CIN3 prevalence at next smear
for uninfected cytologically normal women was much less and
declined with increasing age, from 1.0% (12 out of 1194) below
age 35 to 0.1% (two out of 1584) at age 45 or over. The relationship
between initial HR-HPV infection and neoplasia at the
next smear was analysed by unconditional logistic regression of
the 84 CIN3þ cases whose HPV status at entry was known
(Table 3) using the 4124 HPV typed women in the random cohort
hose next smear was normal as controls (Table 6). The estimated
OR for CIN3þ at the next smear associated with HR-HPV
infection in a normal entry smear was 17.2 (CI 10.4–28.4,
Po0.001). Analysis restricted to the 40 incident CIN3þ cases
(Table 6) in the random cohort gave a similar OR estimate (OR
Table 5 Annual incidence of new cases of CIN3+ in women with a
screening interval of less than 5 years following a normal smear
Age at
mid-point
of interval
No. of CIN3+
diagnosed at
next smear
Woman-years
from last
smear to
next smear
Incidence
per 1000
per year
Cumulative
CIN3+ risk
at start of
interval
(%)
15–19 8 5129 1.56 0.0
20–24 50 22487 2.22 0.8
25–29 94 23074 4.07 1.9
30–34 72 19623 3.67 3.9
35–39 42 17239 2.44 5.8
40–44 23 15065 1.53 7.0
45–49 10 11785 0.85 7.8
50–54 7 9257 0.76 8.2
55–59 4 6861 0.58 8.6
60–64 1 5253 0.19 8.9
65–69 2 1437 1.39 9.0
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Figure 4 Cumulative risk of CIN3 or cancer among 232 cytologically
normal women with HR-HPV infection at entry.
Table 6 High-risk HPV prevalence at entry in the random cohort among
women with a normal entry smear and an adequate subsequent smear
Next smear result
Age at
next smear Normal CIN3+ CIN2
Lesser
abnormality
All
women
HR
a HPV positive at entry
o35 144 (87.8%) 11 (6.7%) 0 (0.0%) 9 (5.5%) 164
35–44 35 (76.1%) 5 (10.9%) 2 (4.4%) 4 (8.7%) 46
45+ 17 (77.3%) 4 (18.2%) 0 (0.0%) 1 (4.6%) 22
All ages 196 (84.5%) 20 (8.6%) 2 (0.9%) 14 (6.0%) 232
HR
a HPV negative at entry
o35 1109 (92.9%) 12 (1.0%) 9 (0.8%) 64 (5.4%) 1194
35–44 1283 (95.1%) 6 (0.4%) 3 (0.2%) 57 (4.2%) 1349
45+ 1536 (97.0%) 2 (0.1%) 2 (0.1%) 44 (2.8%) 1584
All ages 3928 (95.2%) 20 (0.5%) 14 (0.3%) 165 (4.0%) 4127
All women 4124 (94.6%) 40 (0.9%) 16 (0.4%) 179 (4.1%) 4359
aHigh-risk HPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68.
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repeated with lesser cytological abnormality as the outcome event.
The prevalence of HR-HPV infection in the normal entry smear
was 8% (14 out of 179) among women whose follow-up smear
showed lesser abnormality, and the corresponding odds ratio was
1.4 (CI 0.8–2.5). Although based on only 16 incident CIN2 cases
for whom HPV at entry was determined, the corresponding
analysis for women who developed CIN2 gave similar results. The
prevalence of HR-HPV in their normal entry smears was 13% (two
out of 16) and the CIN2 odds ratio for prior HR-HPV infection was
2.3 (CI 0.5–10.7).
HPV type-specific risk
It has long been recognised that genital (and other) HPVs can be
classified phylogenetically into groups (Van Ranst et al, 1992)
that confer different risks of disease (Lorincz et al, 1992). Table 7
shows the distribution of HPV types among 266 HPV-infected
women with CIN3þ at entry and in the 561 carriers in the random
cohort who did not have CIN3þ at entry. The risk is highest for
HPV 16, which constituted 68% of HPV infections among CIN3þ
patients but only 31% among unaffected carriers. The OR is three
to four times lower for the 27% of CIN3þ cases infected with
other oncogenic HPV types in the same class as HPV16 or the
HPV18-related class. Other HPV types account for 33% of
prevalent infections but only 4% of CIN3þ cases. The prevalence
of CIN3þ at the following smear was thus highest for women with
HPV16.
A second spatula was not obtained for most women in the
cohort, and HPV status at the following routine smear could
be determined for only 86 women who were cytologically
normal but HR-HPV positive at entry. The proportion still
infected with the same HR-HPV type at their following
smear was 31% (27 out of 86). All eight women who were initially
HR-HPV positive and were diagnosed with CIN3 at their following
smear had the same HR-HPV type in both samples (seven
HPV16, one HPV18). The same HR-HPV type was detected at
entry and at the next smear in 21 (32%) of the 65 women whose
next smear was taken after an interval of more than 2 years. The
next smear was abnormal in 13 (62%) of these 21 women with
persistent HR-HPV, including eight with CIN3þ, two with CIN2
and three with lesser abnormality. HPV16 was more likely to
persist than other HR-HPV types. The proportion of women with
HR-HPV at entry who still had the same HPV type at their next
smear was 53% (18 out of 34) for HPV16, 26% (nine out of 35) for
HPV18, HPV31 or HPV33 and none of 27 for all other HR-HPV
types.
DISCUSSION
HPV detection predicts CIN3 but not lesser abnormality
The relationship between HR-HPV infection at entry and low-
grade abnormality at the next smear was weaker in this study (OR
1.4, CI 0.8–2.5) than in several other cohorts (Liaw et al,
1999),(Kjaer et al, 2002), (Schlecht et al, 2001). This difference is
at least partly due to the longer screening intervals in Manchester,
which gave most transient HPV infections and their associated
lesions time to disappear. In the Portland cohort with a policy of
annual screening, the prevalence of HPV infection at entry among
women who subsequently developed ASCUS or LSIL declined from
60% for screening intervals of 17 months or less to 24% for
intervals of 3 years or longer (Liaw et al, 1999). Cytologically
normal women with HPV infection at entry also had a higher risk
of dysplasia in smears taken after a shorter interval than in later
smears in other cohorts (Schlecht et al, 2001; Kjaer et al, 2002). In
addition, our lesser abnormality category included some mildly
abnormal smear reports that would have been excluded by the
rigorous pathological review conducted in these three cohorts. The
combined prevalence of HR-HPV at diagnosis was 64% for ASCUS
or worse smears in Portland (Sherman et al, 2003) and only 44%
for all abnormal smears in our study (Table 2). Any relationship
between HPV infection and later risk of low-grade lesions was
further reduced in Manchester by the exclusion from our lesser
abnormality category of smears that were followed within 2 years
by histological diagnosis of CIN3þ, most of which contained
HPV.
Sensitivity of HPV testing in primary screening
Our sample collection protocol was not designed for PCR analysis
and was unsatisfactory by modern standards. b-Globin could be
amplified in only 89% of samples, due probably to the inhibitory
effect of the wooden spatula tip, which remained in the sample at
room temperature for several weeks before decanting and freezing.
Among those that were b-globin positive, however, these sampling
and assay methods detected HR-HPV in 82% (257 out of 314) of
the CIN3þ cases diagnosed at an abnormal entry smear (Table 3).
This is similar to the average sensitivity of 84% for HSIL detection
by HPV assay reported in a recent meta-analysis of published
studies (Arbyn et al, 2004). A second spatula was taken before
histological diagnosis from 21 of the 57 women with prevalent
CIN3þ whose initial spatula was HR-HPV negative, and 13 (62%)
were HR-HPV positive. These statistics suggest that about 95% of
CIN3s were HPV positive, but this rate would presumably have
been higher with the lower detection threshold of modern PCR
methods. Regular HPV testing of sufficient sensitivity would thus
detect HR-HPV in almost all CIN3 cases (Nobbenhuis et al, 1999;
Cuzick et al, 2003). The right-hand part of Table 3 shows that the
prevalence of HR-HPV at entry among cytologically normal
women in whom CIN3þ was diagnosed at the next routine smear
was 50% (42 out of 84). More sensitive HPV testing would thus
detect the majority of CIN3þ cases several years before they
become cytologically abnormal. In the Portland study the
prevalence of HR-HPV at entry in cytologically normal women
was 73% in those who developed CIN3þ within 45 months and
38% in those diagnosed later (Sherman et al, 2003). Women with
incipient CIN3 usually shed HPV persistently for several years
before becoming cytologically abnormal (Nobbenhuis et al, 1999),
so cases detected by HPV screening would still be HPV positive on
retesting, and would be referred for colposcopy irrespective of the
rescreening interval.
The sensitivity of our HPV assay must depend on viral load, and
would be lower in women with normal cytology. Using MY-Gold
instead of MY-Taq polymerase increased the HR-HPV detection
rate by 54% in women with normal cytology, but only by 2% in
Table 7 Distribution of HPV types in CIN3s diagnosed at entry, and in
HPV carriers in the random sample who did not have CIN3 at entry.
HPV
type
CIN3+ with
HPV+ve entry
smear
Random sample of
other women
HPV+ve at entry
OR (exact
95% CI)
16 182 (68.4%) 165 (30.6%) 1.00
16 related
a 46 (17.3%) 109 (20.2%) 0.38 (0.25–0.58)
18 18 (6.8%) 62 (11.5%) 0.26 (0.14–0.47)
18 related
b 9 (3.4%) 28 (5.2%) 0.29 (0.12–0.66)
Other HR
c 2 (0.8%) 26 (4.8%) 0.07 (0.01–0.29)
LR and NK
d 9 (3.4%) 150 (27.8%) 0.05 (0.02–0.11)
Total 266 (100%) 540 (100%)
aTypes 31, 33, 35, 52, 58.
bTypes 39, 45, 59, 68.
cOther high-risk HPV types: 26, 51,
53, 56, 66.
dLow risk or unknown HPV types, including generic probe +ve but type
unidentified. When multiple HPV types were detected, women have been
categorised by their highest risk virus according to the ranking in the table.
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prevalence estimates (Table 2) may thus be substantially too low at
each age.
Lifetime HPV and CIN3 rates
The relationship between HPV prevalence based on a single
sample and lifelong risk of infection is not known. Persistent or
recurrent infection is more likely to be detected than a transient
episode due to the length-biased sampling effect. The cumulative
HPV rate was higher than the cross-sectional rate by a factor of 1.6
among American students sampled weekly on 10 occasions
(Wheeler et al, 1996), and by about two-fold among Brazilian
women sampled four times at 4-monthly intervals (Schlecht et al,
2001). The proportion of younger women in our cohort who will
acquire an HR-HPV infection during their lifetime is thus likely to
be at least twice the prevalence of 18% seen in women aged 20–24
(Table 2). At current rates 9% of the cohort will eventually develop
CIN3 (Table 5), although this may be an underestimate, as both
CIN3 and HPV rates appear to have increased over the following
decade. More than 25000 women were recruited to the ARTISTIC
trial of primary HPV screening between 2001 and 2003 through
many of the same clinics in and around Manchester. HR-HPV
prevalence by Hybrid Capture II was 33% at age 20–29, 15% at
30–39, 9% at 40–49 and 6% at 50–69 (Kitchener et al, 2004), more
than double the rate we observed in the same population about 12
years earlier at each age (Table 2). This large increase seems
unlikely to be due entirely to differences in HPV detection
sensitivity. The CIN3 incidence rate in England and Wales at age
20–24 doubled from 1.2 per thousand in 1990 to 2.4 per thousand
in 2000, and the lower prevalence of cervical abnormality in the
retrospective cohort compared with the prospective cohort
(Table 4: OR 0.88, Po0.05) is also consistent with a continuing
increase in HPV prevalence during the 1990s.
Transiently detectable HPV infection is generally regarded as
innocuous, but our long-term follow-up of 232 women with HR-
HPV at entry shows a cumulative CIN3þ diagnosis rate of 16%
after 10 years (Figure 4). A lower CIN3 rate following HPV
detection was seen in the Portland study, where the cumulative
risk of CIN3 or cancer diagnosis among women with HR-HPV
infection and normal cytology at entry was only about 6% after 10
years’ follow-up. The risk in the Portland cohort was even lower
among those who were cytologically abnormal (ASCUS or worse)
at entry after the initial lesion had regressed or been treated
(Sherman et al, 2003). Only one CIN3 was diagnosed in the
Portland study in smears taken between 21 months and 10 years
after entry among 417 HR-HPV positive women with an abnormal
entry smear compared with 38 cases among 2562 women with HR-
HPV infection but normal cytology at entry (OR 0.16, P¼0.03).
This reduction in risk supports the long-standing belief that even
biopsy of HPV lesions may reduce the subsequent risk of CIN3
(Koss et al, 1963). Cervical ablation substantially reduced the risk
of subsequent CIN or cancer when this was a routine procedure in
cytologically normal women (Vonka et al, 1984). This protective
effect, combined with an annual screening policy under which a
substantial proportion of HR-HPV-infected women will eventually
be detected with dysplasia, may account for the lower overall CIN3
risk among infected women in the Portland study. The increased
CIN3 risk among women in Manchester with a history of cervical
abnormality (OR 3.0: Table 4) presumably reflects their high
probability of having an HR-HPV infection, and perhaps also a
lower probability in Britain than in the US that their dysplasias
were biopsied or destroyed.
Cytological regression of CIN3
The CIN3 prevalence in smears taken more than 5 years after a
normal smear appears to have reached a plateau at about 1%
(Table 4 and Figure 2). The initial linear increase in CIN3
prevalence with increasing screening interval shows that CIN3
often remains detectable for at least 5 years, but this subsequent
plateau suggests that most cases eventually regress cytologically.
The rising prevalence thus represents a balance between increasing
CIN3 incidence and cytological regression. The inference that most
CIN3s are only transiently detectable is supported by the low
prevalence of CIN3 in women aged 45 or older with no record of a
previous smear, which was only 0.5% (Table 1; 11 out of 2087). A
proportion of these women would have had unrecorded smears,
but the CIN3 incidence rates in Table 5 suggest that 8% of women
in this cohort develop CIN3 by age 45. Most earlier CIN3s must
therefore have regressed cytologically by the time these unscreened
women entered our study. Even in the high-risk rural population
of Costa Rica, the prevalence of persistent HSIL at initial
recruitment was less than 1% above age 45 (Herrero et al, 2000).
Reversion to cytological normality in women with underlying
carcinoma in situ was observed directly in the prospective study of
Dutch women referred for colposcopy with abnormal smears, in
which six of the eight women who regressed to normal cytology
and colposcopy but remained HR-HPV positive had occult CIN3
(Nobbenhuis et al, 1999).
The underlying risk in women who choose not to be screened
may differ between different populations. The CIN3 rate at entry in
women with no previous smear history was similar to that in the
screened population both in our cohort (Table 1) and in a
Norwegian study (Forsmo et al, 1996), and the rate at their second
smear was slightly less than in previously screened women
(Table 4). A much lower CIN3 rate was observed at the second
smear than at entry in a national study of inadequately screened
low-income American women (Sawaya et al, 2003), but this may
reflect confounding between screening interval and number of
negative smears. Above age 30 both CIN3 and cancer were slightly
less common in unscreened women in the American study (Sawaya
et al, 2003) than in our cohort (Table 1), and CIN3 prevalence after
a negative smear was similar to the rate we observed for screening
intervals of under 2 years (0.35%: Table 4).
National data linkage
The underlying age-specific incidence rate of new cases of CIN3 in
Manchester shown in Figure 3 could be estimated in the same way
in any population with routine screening records linked to
histology records. This could now be done for the whole of
Britain, as the computerised call–recall system introduced in 1988
includes details of almost all cervical smears for the whole
population aged 20–64. Individual women’s smear records are
already linked to histological diagnoses of CIN3 in the computer
systems of the cytology laboratories that provide these data.
Linkage to cancer registrations and deaths would provide CIN3
incidence as well as cancer incidence and mortality rates by
screening interval and age in all regularly screened women,
complemented by cancer rates in the inadequately screened
remainder of the population. Sasieni and Cuzick (2001) recom-
mended that such audit should be established as a routine
procedure. The files could also be linked to small area statistics
such as deprivation index that can be derived from address
postcodes. The files would be anonymised after linkage, so
informed consent would not be needed for such analyses.
Progression to carcinoma in situ and cancer
Three observations within our cohort reflect the distinction
between the majority of HR-HPV infections that resolve within a
year or two and the minority that persist and frequently progress
to CIN3 (Nobbenhuis et al, 1999). First, the prevalence of CIN3
increases linearly with time since the last normal smear, at least up
to 5 years, while that of lesser (low-grade) abnormality is almost
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very strong relationship between HR-HPV infection at entry in
cytologically normal women and the risk of CIN3þ at their next
smear (OR 17.2, Po0.001), but a much weaker and nonsignificant
relationship for abnormalities other than CIN3þ (OR 2.3 for CIN2
and 1.4 for lesser abnormality). Third, the much lower incidence of
CIN3 in women aged under 25 despite their higher HPV prevalence
compared with those aged 25–34 (Figure 3) indicates a substantial
delay between initial HPV infection and the development of
carcinoma in situ. In a case–control study nested within the
cohort (Deacon et al, 2000), the number of sexual partners was the
main risk factor for detectable HPV infection, but progression to
CIN3 diagnosis among HPV-infected women depended more on
early age at first intercourse, providing further evidence that
carcinoma in situ often originates in a much earlier HPV infection.
An increase in prevalence of CIN2 and CIN3 but not of lesser
abnormality with increasing interval since the last normal smear
was reported in Icelandic women, but data for CIN2 were not
presented separately (Sigurdsson and Adalsteinsson, 2001). There
are several epidemiological differences between CIN2 and CIN3.
The CIN2:CIN3þ ratio was 1.5 (19:13) in smears taken within 18
months of a normal smear and 0.5 (211:415) for longer intervals
(Po0.005). CIN2 is also commoner in young women. The
CIN2:CIN3þ ratio fell from 1.1 (58:53) below age 25 to 0.5
(142:308) at older ages (Table 1; Po0.001). Persistently detectable
HPV preceding cytological abnormality is common in the
development of CIN3 and cancer but not of CIN2. In a prospective
cytological and colposcopic follow-up of women in the Nether-
lands with abnormal smears (Nobbenhuis et al, 1999), the
proportion of incident cases that were preceded by persistent
HR-HPV infection was 95% (98 out of 103) for CIN3, but only 27%
(eight out of 30) for CIN2 and 10% (six out of 63) for CIN1. HR-
HPV was detected in the preceding normal smear in 50% (Table 3:
42 out of 84) of CIN3s and in 13% (Table 6: two out of 16) of CIN2s
in our cohort (Po0.01). Despite disagreement between patholo-
gists over the classification of individual cases, these objective
differences between CIN2 and CIN3 support the view that most
CIN2s are biologically and clinically indistinguishable from the
lower grade HPV lesions that usually regress (Syrjanen et al, 1992).
Among women with HPV infection, these authors observed
progression or recurrence in 81% of CIN3s, 24% of CIN2s and
17% of CIN1s (Syrjanen et al, 1992). The weak increase in CIN2
prevalence with increasing screening interval (Figure 2) confirms
that some cases are persistent, perhaps because they harbour
undetected carcinoma in situ or because they are precursors in its
progression. For clinical purposes, the inclusion of CIN2 with
CIN3 in the HSIL category of the Bethesda classification may
therefore be justified, although a repeat smear would avoid
colposcopy and biopsy in the transient majority of CIN2s
(Syrjanen et al, 1992). Epidemiological studies in which CIN2
and CIN3 are combined are unnecessarily uninformative, however,
particularly in younger women or if the screening interval is 18
months or less. Clonality, HPV integration, loss of heterozygosity
and patterns of gene expression are likely to reflect different stages
of carcinogenic progression (Evans and Cooper, 2004), and results
for CIN2 and CIN3 should also be presented separately in cellular
and molecular studies. It is perhaps unfortunate that the earlier
categories of severe dysplasia and carcinoma in situ were
superseded (Syrjanen et al, 1992), despite difficulties of reprodu-
cibility (Sherman, 2003).
The age-specific CIN3 incidence pattern shown in Figure 3
suggests a simple model for the relationship between CIN3 and
invasive cancer. Before the introduction of the national screening
programme in 1988, cervical cancer death rates in Britain rose
sharply up to about age 45, then remained almost constant above
age 50 within each birth cohort (Peto et al, 2004). The cumulative
risk of developing CIN3 (Table 5) shows a similar pattern. In view
of this similarity and the effectiveness of regular screening in
preventing cervical cancer, it seems likely that the incidence of
cervical cancer remains roughly constant at about 1% per year for
the rest of their lives in women who have developed undiagnosed
CIN3, and about 40% will eventually develop invasive cancer (Peto
et al, 2004).
Implications for screening policy
If most CIN3s eventually regress cytologically, an increasing
proportion will be missed as the screening interval increases and
many may not reappear until they become malignant. CIN3
regression is also relevant in choosing the age at which screening
should begin. The age at which routine screening begins has
recently been raised from 20 to 25 years in the UK, and it has been
suggested that this should be further increased to 30 years because
invasive cancer is so rare in young women (Miller, 2002).
Registered CIN3 rates for England for 2000 imply that 2.9% of
women are now diagnosed with histologically confirmed CIN3 by
age 30, and the underlying risk must be even higher, as coverage is
still incomplete. If screening began at age 30, therefore, at least 3%
of women would already have had undiagnosed CIN3. Table 5
suggests that 3.9% of women in our cohort develop CIN3 by age
30. The majority of such cases may no longer be cytologically
detectable at age 30, as the prevalence of CIN3 in women with no
previous smear (Table 1) was only 0.8% (16 cases) at age 25–29
and 1.1% (9 cases) at age 30–34.
CIN3 in an older woman who has not been screened regularly
may often be a recurrence of an earlier undiagnosed lesion. The
CIN3 rate in England was increasing at all ages before 1988, but the
rate among women aged over 45 has fallen progressively since the
introduction of national screening. Women whose CIN3 has
already regressed before their first smear and does not recur may
suffer an increased risk of invasive cancer for the rest of their lives,
and this long-term risk could be an important disadvantage of
delaying the age at which routine screening begins (Peto et al,
2004).
Our results support the conclusion that the screening interval
should be less than 5 years, except perhaps for older women who
are HPV negative, whose risk of CIN3 is very low (Table 6). Our
analysis suggests that more frequent screening will have little effect
on the overall number of CIN3 cases diagnosed in a regularly
screened population. More frequent screening will prevent more
CIN3s by ablation of lesser lesions; but it will also detect more
before they have regressed cytologically, and will therefore reduce
cancer incidence. The anomalous long-term protective effect of
abnormal cytology among HPV-infected women in Portland
suggests that the annual cytology, routine colposcopy of ASCUS
and more frequent ablative treatment still practised by most
American gynaecologists (Noller et al, 2003) will over time lead to
a reduction in CIN3 incidence. The additional reduction in
invasive cancer achieved by annual rather than 3-yearly screening
is likely to be small (Sawaya et al, 2003), however, and many
lesions that are HPV-negative and hence harmless will also be
treated. Sensitive HPV testing is therefore a useful adjunct to
cytology (Cuzick et al, 1995), as mildly abnormal smears that do
not contain HR-HPV can be identified and ignored (Cox et al,
2003). The potential superiority of HR-HPV testing over cytology
for sensitive primary screening is now widely recognised. Very
sensitive HPV testing will reduce still further the CIN3 or cancer
risk in HPV-negative women and increase the proportion of CIN3s
that are preceded by persistent HPV detection, but it is also likely
to increase the number of referrals for colposcopy. Other practical
questions that must be resolved before HPV testing can replace
cytology are the appropriate screening interval, whether HR-HPV
infection should be observed or treated immediately by cervical
ablation, and whether cytology is worthwhile in addition to HPV
testing.
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yParticipating clinics
Manchester: Abbey Hey Clinic, Alexandra Park Health Centre,
Ancoats Community Clinic, Ancoats Hospital, Assheton Road
Clinic, Atherton Clinic, Baguley Clinic, Beswick Health Centre,
Bodey Medical Centre, Boothtown Clinic, Brunswick Clinic,
Central Drive Clinic, Charlestown Health Centre, Child Health
Centre, Clayton Health Centre, Corporation Road Clinic, Crump-
sall Clinic, Derbyshire House Clinic, Gorton Combined Clinic,
Harpurhey Health Centre, Hulme Clinic, Irlam Health Centre,
Ladybarn Group Practice, Levenshulme Health Centre, Little
Hulton Clinic, Longsight Health Centre, Monton Road Clinic,
Moss Side Health Centre, Newton Heath Health Centre, Nicholas
Road Health Centre, Northenden Group Practice, Northern
Hospital, Partington Lane Clinic, Plant Hill Clinic, Poplar Street
Clinic, Robert Darbyshire Practice, Smedley Street Clinic, St Mary’s
Hospital, The Palatine Centre, Varley Street Clinic, Walkden Clinic,
Walmer Street Clinic, Wellwoman Clinic, Wilmslow Road Clinic,
Woodhouse Park Clinic, Wythenshawe Health Care Centre.
Rochdale: Whitworth Medical Centre. Salford: Bevendon Square
Clinic, Higher Broughton Health Centre, Hope Hospital, Lance-
burn Health Centre, Liverpool Street Clinic, Lower Broughton
Clinic, Ordsall Health Centre, Langworthy Clinic. Stockport:
Adswood Clinic, Bramhall Clinic, Brinnington Clinic, Burley
House Clinic, Cheadle Heath Clinic, Hazel Grove Clinic, Heaton
Norris Clinic, Maple Clinic, Marple Cottage Surgery, North
Reddish Clinic, Offerton Clinic, Offerton Green Clinic, Robins
Lane Medical Centre, Romiley Clinic, Romiley Health Centre, Shaw
Heath Clinic, Stepping Hill Clinic, Wellwoman Clinic, Woodley
Clinic, Bredbury Clinic, Brookfield Clinic, Heaton Norris Clinic.
Warrington: Derby Road Clinic. Wigan: Beech Hill Health Centre,
College Road Clinic, Grasmere Street Health Centre, Haig Road
Clinic, Liverpool Road Health Centre, Longshoot Lane Health
Centre, Orrell Road Clinic, Pemberton Clinic, Platt Bridge Clinic,
Queens Road Clinic, Standish Clinic
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